Tau-aggregation and neuroinflammation-IN-1
Tau-aggregation and neuroinflammation-IN-1 is a potent tau-aggregation and neuroinflammation inhibitor. Tau-aggregation and neuroinflammation-IN-1 exhibits remarkable inhibitory activities against AcPHF6 and full-length tau aggregation. Tau-aggregation and neuroinflammation-IN-1 has a low cytotoxicity and reduced NO release in LPS-stimulated BV2 cells. Tau-aggregation and neuroinflammation-IN-1 can reverse okadaic acid-induced memory impairment in rats[1].
Product Specifications
CAS Number
[2175953-98-5]
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Microtubule/Tubulin
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/tau-aggregation-and-neuroinflammation-in-1.html
Concentration
10mM
Purity
99.97
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(O)C1=CC=C(N2N=C(C)C3=C2C=C(OC4=C(C(C)=O)C(O)=C(C)C(O)=C45)[C@]5(C)C3=O)C=C1
Molecular Formula
C25H20N2O7
Molecular Weight
460.44
Precautions
H302, H315, H319
References & Citations
[1]Shi CJ, Peng W, Zhao JH, et al. Usnic acid derivatives as tau-aggregation and neuroinflammation inhibitors. Eur J Med Chem. 2020;187:111961.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Browse additional items from our catalog
LYPD5 (LY6/PLAUR Domain Containing 5, FLJ30469, PRO4356) (MaxLight 405)
LYPD5 (LY6/PLAUR Domain Containing 5, FLJ30469, PRO4356) (MaxLight 405)
REXO1L5P sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
